CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
137 hedge funds and large institutions have $328M invested in Cymabay Therapeutics in 2019 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 38 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
137
Holders Change
+4
Holders Change %
+3.01%
% of All Funds
3.01%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
19
Increased
43
Reduced
38
Closed
15
Calls
$5.58M
Puts
$44K
Net Calls
+$5.54M
Net Calls Change
-$997K
Top Buyers
| 1 |
Millennium Management
New York
|
+$3.79M |
| 2 |
JPMorgan Chase & Co
New York
|
+$2.38M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.34M |
| 4 |
Morgan Stanley
New York
|
+$2.14M |
| 5 |
Citigroup
New York
|
+$2.1M |
Top Sellers
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$15.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$12M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.78M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$2.87M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$2.62M |
